Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Polyphenon E - Aresus Pharma/Epitome Pharmaceuticals

Drug Profile

Polyphenon E - Aresus Pharma/Epitome Pharmaceuticals

Alternative Names: Polyphenon E; SB 03; Sinecatechins; Veregen

Latest Information Update: 03 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mitsui Norin; Polyphenon Pharma
  • Developer Emory University; Maastricht University; MediGene AG; Polyphenon Pharma; SynCore Biotechnology; Triton Pharma; Will-Pharma
  • Class Antineoplastics; Antivirals; Catechins; Herbal medicines
  • Mechanism of Action Antioxidants; Immunostimulants; Viral fusion protein inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Genital warts
  • Phase II/III Basal cell cancer
  • Phase II Prostatic intraepithelial neoplasia
  • No development reported Bladder cancer; Head and neck cancer
  • Discontinued Actinic keratosis; Angina pectoris; Chronic lymphocytic leukaemia

Most Recent Events

  • 01 Jun 2019 Adverse events and efficacy data from a phase I trial in Head and neck cancer presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO-2019)
  • 09 Apr 2019 Polyphenon E licensed to Aresus Pharma in World (excluding USA)
  • 09 Apr 2019 Medigene AG plans for the closing of the transaction including the transfer of rights to Aresus Pharma in mid April 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top